unresectable hepatocellular carcinoma Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1 (1)
Phase 2 (1)

Interventional (2)

BeiGene (1)
Shanghai Zhongshan Hospital (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadcancer

I am/have/hadhepatocellular carcinoma

I am/have/hadcarcinoma

I am/have/hadunresectable hepatocellular carcinoma

I am/have/hadliver cancer

I am/have/hadcholangiocarcinoma

I am/have/hadmetastatic hepatocellular carcinoma

I am/have/hadhepatocellular carcinoma metastatic

I am/have/hadmicrowave ablation

added new label for I am/have/had

more

I am looking for

I am looking forTACE

I am looking forlenvatinib

I am looking forsintilimab

I am looking forpd-1 inhibitor

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.

sintilimab

TACE

carcinoma

hepatocellular carcinoma

pd-1 inhibitor

0 views
16 Feb, 2024
1 location

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Endocrinology
Recruiting

Preliminary Antitumor Activity Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

The primary objective of this study is to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).

cholangiocarcinoma

carcinoma

hepatocellular carcinoma metastatic

liver cancer

unresectable hepatocellular carcinoma

0 views
05 Aug, 2020

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.